XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
  Virology
  Bacteriology
   Salmonella
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Bacteriology Channel
subscribe to Bacteriology newsletter

Latest Research : Microbiology : Bacteriology

   DISCUSS   |   EMAIL   |   PRINT
Rapid tests for meningitis and MRSA are being developed
Oct 17, 2005, 19:21, Reviewed by: Dr.

Current hospital tests take up to 72 hours, by which time the patients may have become seriously ill and may have spread the disease.

 
Rapid tests for serious disease such as meningitis, chlamydia and the hospital superbug MRSA are being developed by a new company, Atlas Genetics Ltd, which is being launched using £500,000 funding and the expertise of academics at the University of Bath.

Current hospital tests take up to 72 hours, by which time the patients may have become seriously ill and may have spread the disease.

Patents have been filed in relation to Atlas’s key technology and it is expected that it will enable hospitals and eventually GPs to perform tests on the spot and make decisions about treatment within 20 minutes. The potential market for Atlas’s products is valued at over $3 billion (£1.7 billion) and is growing rapidly.

The company is working on a product that will analyse a clinical sample of blood, urine or saliva using a test cartridge inserted into a small, portable instrument.

The basis of this sensitive and specific test is an electronic tag developed by the company that automatically indicates the presence of DNA from the bacteria causing the disease.

This innovative technology has been developed over the last three years with a team of leading scientists from the Department of Chemistry at the University of Bath, including Professor Laurie Peter, Dr Toby Jenkins, Dr Chris Frost and Dr Stephen Flower. This was in collaboration with companies now acquired by Osmetech Plc, which is also a party to the current joint venture.

The commercial and technical management team of Dr John Clarkson, Dr Gordon Forrest, Dr Russ Keay, Alison Kibble and Karen Yates is highly experienced and have held senior positions in medical diagnostics, health care marketing, product development and finance.

The £500,000 already raised came in part from the Sulis Seedcorn Fund, which provides support for the new businesses set up using research carried out by the Universities of Bath, Bristol and Southampton. The Sulis institutional investment matched a £250,000 investment from a private investor who was introduced by the South West Angel and Investor Network (SWAIN), which brings together investors and companies seeking equity funding in the South West region.

Atlas was set up with the guidance and support of the University's Research and Innovation Services, which markets the University's resources of people, facilities and intellectual property to generate funds in support of research and teaching.
 

- University of Bath, UK
 

www.bath.ac.uk

 
Subscribe to Bacteriology Newsletter
E-mail Address:

 

About Sulis The £9 million Sulis Seedcorn Fund is the largest University Challenge Fund in the country. The Fund, owned by the Universities of Bath, Bristol and Southampton and managed by Quester, provides support for the early stage commercialisation of research generated by the academic communities of the universities through enhancing the commercial potential of specific products or services as well as the licensing or sale of intellectual property and the formation of spin-out companies. Investments have taken a variety of forms, including conventional equity and loan funding for spinout companies and “proof of concept” project funding directly into academic groups within the universities to develop technology to a point where it can be licensed to a commercial partner. The fund has been in existence since 2000 and has a portfolio now of some 23 spin-out companies and a further 10 University IP investments. See www.bath.ac.uk/sulis-innovation Contact: Rona Wagstaffe Telephone: 01225 388681 e-mail:[email protected]

The University of Bath is one of the UK's leading universities, with an international reputation for quality research and teaching. In 16 subject areas the University of Bath is rated in the top ten in the country.


Related Bacteriology News

Gut Bacteria Cospeciating with Plataspid stinkbug
An infectious agent of deception, exposed through proteomics
Gram positive bacterial membrane mystery solved
Salmonella bacteria use RNA to assess and adjust magnesium levels
How deadly toxin botulinum neurotoxin A hijacks cells
String Test: Effective and Inexpensive Method for Detecting Helicobacter pylori
Scientists develop biosensor to detect E. Coli bacteria
Found - bacteria with strange magnetic personality
Student discovers protein in yoghurt that fights E. coli
Slugs May Spread E. coli to Salad Vegetables


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us